LBH589: Clinical Trials

52 trials of LBH589, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

28 completed, 19 terminated, 3 withdrawn, 2 unknown. 52 Phase 2, 16 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 252Completed 28, Terminated 19, Withdrawn 3, Unknown 2
Phase 116Completed 10, Terminated 3, Unknown 2, Withdrawn 1

Follow LBH589: new trials by email Literature Review of LBH589 trials Research Report on LBH589

Trials (filtered) newest first · largest first

All 52 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Carfilzomib, Chemosensitivity Assay, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Phase 2TerminatedUniversity of Washington92018-02-082022-05-09
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
Panobinostat, Carfilzomib, Lenalidomide - Multiple Myeloma
Phase 1 / Phase 2WithdrawnH. Lee Moffitt Cancer Center and Research Institute2017-06-012017-04-25
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Dexamethasone, Panobinostat, Liposomal vincristine - Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's
Phase 2TerminatedSt. Jude Children's Research Hospital32016-11-232019-04-03
Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)
Panobinostat - Multiple Myeloma
Phase 2CompletedH. Lee Moffitt Cancer Center and Research Institute302016-06-102022-11-01
Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy
Panobinostat, Pegylated Interferon-alpha2a - HIV Infection
Phase 1 / Phase 2CompletedMassachusetts General Hospital172016-05-012024-02-28
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets - Multiple Myeloma
Phase 2Completedpharmaand GmbH2482016-04-272024-07-12
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride - Plasma Cell Leukemia, Plasmacytoma
Phase 2CompletedM.D. Anderson Cancer Center832015-09-142025-03-18
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
Panobinostat, Ruxolitinib - Myelofibrosis
Phase 1 / Phase 2CompletedJohn Mascarenhas152013-01-012023-10-31
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
Panobinostat - HIV Infection
Phase 1 / Phase 2CompletedUniversity of Aarhus152012-09-012014-02-25
Panobinostat Biological Correlates Study
panobinostat - Nodal Lymphoma, Lymphoma With Cutaneous Involvement
Phase 2CompletedPeter MacCallum Cancer Centre, Australia302012-07-162022-05-06
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
Panobinostat, Lenalidomide, Dexamethasone - Multiple Myeloma
Phase 2CompletedAjai Chari322012-07-012018-04-09
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
RAD001, LBH589, Doublet (RAD001 and LBH589) - Diffuse Large B-cell Lymphoma
Phase 2TerminatedAnne Beaven, MD502012-02-012016-11-25
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma
panobinostat, lenalidomide - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma
Phase 2CompletedOhio State University Comprehensive Cancer Center242011-10-132017-11-14
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Panobinostat with Rituximab - Diffuse Large B Cell Lymphoma
Phase 2TerminatedMassachusetts General Hospital182011-06-012017-05-09
Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT
Panobinostat - Diffuse Large B-cell Lymphoma
Phase 2CompletedFondazione Italiana Linfomi - ETS352011-02-012019-11-22
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
panobinostat, laboratory biomarker analysis, western blotting - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Phase 2CompletedMayo Clinic412011-01-172022-05-24
Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Panobinostat - Myelodysplastic Syndrome, Acute Myeloid Leukemia
Phase 1 / Phase 2UnknownJohann Wolfgang Goethe University Hospital622011-01-012018-03-20
A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)
LBH589, Rituximab - Diffuse Large B Cell Lymphoma
Phase 2CompletedSarit Assouline422010-11-012023-03-24
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Bortezomib, Panobinostat - Pancreatic Cancer
Phase 2TerminatedMasonic Cancer Center, University of Minnesota72010-09-012017-12-28
Re-expression of ER in Triple Negative Breast Cancers
Decitabine, LBH589, Tamoxifen - Breast Cancer, Breast Tumors
Phase 1 / Phase 2TerminatedEmory University52010-07-012015-01-26

Showing 20 of 52. Sign in to see all of them.

Conditions studied

Multiple Myeloma (12)  ·  Recurrence (7)  ·  Lymphoma, Large B-Cell, Diffuse (6)  ·  Myelodysplastic Syndromes (5)  ·  Hodgkin Disease (4)  ·  Lymphoma, T-Cell, Cutaneous (4)  ·  Mycosis Fungoides (4)  ·  Sezary Syndrome (4)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Lymphoma (3)  ·  Lymphoma, Mantle-Cell (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Primary Myelofibrosis (3)  ·  Waldenstrom Macroglobulinemia (3)

Sponsors

Novartis Pharmaceuticals (12)  ·  H. Lee Moffitt Cancer Center and Research Institute (3)  ·  M.D. Anderson Cancer Center (3)  ·  SCRI Development Innovations, LLC (3)  ·  Massachusetts General Hospital (2)  ·  Mayo Clinic (2)  ·  Ajai Chari (1)  ·  Anne Beaven, MD (1)  ·  Dana-Farber Cancer Institute (1)  ·  Duke University (1)  ·  Emory University (1)  ·  Fondazione Italiana Linfomi - ETS (1)  ·  Johann Wolfgang Goethe University Hospital (1)  ·  John Mascarenhas (1)  ·  Masonic Cancer Center, University of Minnesota (1)

Countries

United States (43)  ·  Germany (9)  ·  Australia (5)  ·  Belgium (4)  ·  Italy (4)  ·  Canada (3)  ·  France (3)  ·  Spain (3)  ·  Brazil (2)  ·  Hungary (2)  ·  Argentina (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Finland (1)  ·  Greece (1)

Top investigators

Ajai Chari, MD (1)  ·  Alessandro Levis, MD (1)  ·  Andrew Cowan (1)  ·  Anna Ferrari, MD (1)  ·  Anne Traynor, M.D. (1)  ·  Anne W. Beaven, MD (1)  ·  Arkadiusz Dudek, MD (1)  ·  Atae Utsunomiya (1)  ·  Celeste Bello, M.D. (1)  ·  Daniel R Couriel, M.D. (1)  ·  Daniel R Kuritzkes, MD (1)  ·  David A Reardon, MD (1)  ·  Geoffrey Uy, M.D. (1)  ·  Gesine Bug, MD (1)

Results publications

PMID 25939707, PMID 21984064, PMID 22072492, PMID 22981498, PMID 23287861, PMID 23701016, PMID 23822537, PMID 23950178, PMID 24135804, PMID 25062770, PMID 25572329, PMID 26423811, PMID 26696749, PMID 27166360, PMID 27740633, PMID 28622959, PMID 29296798, PMID 30830886, PMID 31654285, PMID 31778911, PMID 33301738, PMID 34482353, PMID 39863139

NIH funding

2005 (1), 2008 (1), 2009 (1), 2015 (1), P30CA015083 (1), P30CA015704 (1)